Monday, July 20, 2015

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

The data identify ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression free survival (PFS) in patients. Eighty nine percent of patients expressing higher plasma levels of ferritin and lower plasma levels of IL-8 at baseline were disease progression-free at six months. The data show that biomarker-based patient selection has the potential to optimise clinical outcomes in the treatment of renal cancer. There are 6.3 new cases of renal cancer and 1.7 deaths per 100,000 people in Asia each year.


BNC105 is a novel compound being developed as a vascular disrupting agent (VDA) for the treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. This approach has a number of advantages over classical chemotherapy, including stronger impact on tumour cell death, applicability to a wider variety of cancers, and lowered risk of the emergence of therapy-resistant tumour cells.


No comments: